BeOne Medicines, formerly BeiGene, is a global oncology company headquartered in Basel, Switzerland, that discovers, develops, manufactures, and commercializes cancer medicines. The company was established by John V. Oyler and Xiaodong Wang and operates research, clinical development, and manufacturing sites across North America, Europe, and Asia-Pacific, and its shares trade on the Nasdaq under the ticker ONC, on the Hong Kong Stock Exchange, and on the Shanghai Stock Exchange STAR Market.
The company focuses on hematology and solid tumors, with marketed medicines including BRUKINSA (zanubrutinib), TEVIMBRA (tislelizumab-jsgr), and BEQALZI (sonrotoclax), and more than 30 investigational medicines in clinical development. Its medicines hold regulatory approvals in more than 75 countries, and the company reports reaching about 1.8 million patients worldwide with roughly 12,000 employees across six continents.
